Abbott Gmbh & Co Kg

Abbvie Biotechnology Ltd

Basf Aktiengesellschaft

Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Daniel Edward Tracey

Subhashis Banerjee

Jochen G Salfeld

Geertruida Machteld Veldman

Boris Labkovsky

Zehra Kaymakcalan

Michael White

Michael Roguska

Paul Sakorafas

Nicholas W Warne

Angela Widom

Thor Las Holtet

Elaine Joy Derbyshire

Sara Carmen

John Gawain Elvin

Alexander Robert Duncan

Michael Paskind

Stephen Smith

Sarah Leila Du Fou

Stuart Friedrich

Amy Venturini

Angela Myles

Mark Weinberg

Rebecca S Hoffman

Steven Alan Fischkoff

Elliot Keith Chartash

George Richard Granneman

Philip Yan

Lori K Taylor

Anwar Murtaza

William T Barchuk

Clive E Spiegler

Angela Kantor

Tariq Ghayur

Les Sekut

Adam Carter

Steven Fischkoff

Eliot Keith Chartash

The invention describes methods of treating erosive polyarthritis comprising administering a TNF&#x3b1; antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Use of TNF&#x3b1; inhibitor for treatment of psoriasis

Use of TNF&#x3b1; inhibitor for treatment of psoriatic arthritis

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind the P40 subunit of human IL-12 and methods for using the same

Use of TNF-alpha inhibitor for treatment of psoriasis

Methods of treatment using human antibodies that bind IL-12

Human antibodies that bind human interleukin-12

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Human antibodies that bind human IL-12

Human antibodies that bind human IL-12 and methods for producing

Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-.gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-.gamma. inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-.gamma. in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

Methods and compositions for modulating responsiveness to corticosteroids

Growing community of inventors

Harvard, MA, United States of America

Daniel Edward Tracey